0HB0 Stock Chart & Stats
$35.37
-$0.84(-2.32%)
At close: 4:00 PM EDT
$35.37
-$0.84(-2.32%)
Day’s Range― - ―
52-Week Range$22.40 - $45.81
Previous CloseN/A
Volume429.00
Average Volume (3M)711.00
Market Cap
$2.00B
Enterprise Value$1.62K
Total Cash (Recent Filing)$617.58M
Total Debt (Recent Filing)$31.17M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Oct 29, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.01
Shares Outstanding59,701,880
10 Day Avg. Volume376
30 Day Avg. Volume711
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.33Price Target Upside16.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.86
Revenue Forecast (FY)$174.87M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginSustained high top-line growth paired with ~82% gross margins indicates the company’s products have strong unit economics and pricing power. Over 2–6 months this supports reinvestment in commercial scale-up and reduces dependency on immediate margin improvement to reach durable revenue expansion.
Robust Liquidity And Low LeverageA cash runway above $1B and minimal debt provide financial flexibility to fund clinical programs, commercial launches, and regulatory obligations without near-term refinancing. This materially lowers solvency risk and gives management time to execute pivotal catalysts over months.
Commercial Launch Execution And Regulatory PathwaySuccessful REMS-enabled launch momentum plus a planned accelerated sNDA signals both commercialization capability and a clear regulatory path to broaden indications. These structural steps can expand addressable patient populations and drive sustainable product revenue over the medium term.
Bears Say
Large Persistent Cash BurnConsistent multi-hundred-million operating and free cash outflows mean the company will rely on its cash reserve or external financing to sustain operations until profitable. Over 2–6 months this elevates dilution and budgeting risk, constraining discretionary R&D or commercial expansion if burn persists.
Concentration In U.S. Sales And Limited Ex-U.S. FootprintHeavy dependence on U.S. revenue exposes the company to single-market reimbursement dynamics and payer timing. Limited and volatile ex-U.S. sales reduce geographic diversification, slowing global uptake and leaving growth sensitive to U.S. access and policy implementation over coming quarters.
Development And Regulatory Uncertainty (tebapivat Exposure)A meaningful pharmacokinetic exposure shortfall and the need for confirmatory trials increase technical and regulatory risk, potentially requiring higher doses, additional studies, or delayed approvals. These issues can raise program costs and compress the timeline to commercial realization.
Agios Pharma News
0HB0 FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest share price was $22.40 and its highest was $45.81 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $2.00B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Oct 29, 2026 which is in 75 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.655 by -$0.035.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Agios Pharma dividends here
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.21.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.655. Following the earnings report the stock price went down -5.966%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in GB:0HB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.33 (16.86% Upside)
$41.33 (16.86% Upside)
Blogger Sentiment
Bullish
GB:0HB0 Sentiment 80%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.66%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
0HB0 Company Deck
0HB0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.View all GB:0HB0 earnings summaries0HB0 Stock 12 Month Forecast
Average Price Target
$41.33
▲(16.86% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Beam Therapeutics
―
Nurix Therapeutics
―